• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: APOLLO ENDOSURGERY ORBERA INTRAGASTRIC BALLOON SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

APOLLO ENDOSURGERY ORBERA INTRAGASTRIC BALLOON SYSTEM Back to Search Results
Model Number B-4800
Device Problem Insufficient Information (3190)
Patient Problem Hiccups (1899)
Event Date 09/24/2017
Event Type  Injury  
Manufacturer Narrative
Further information has been requested of the initial reporter regarding: device information and patient information.To date, no additional information has been received by apollo.Device labeling addresses the reported event as follows: precautions: antiemetics, antispasmodic, and anticholinergic drugs may be prescribed to lessen the early placement symptoms such as nausea, vomiting, and abdominal pain.Patients will need to immediately contact their physician for any severe or unusual symptoms.Placement of the balloon within the stomach produces an expected and predictable reaction characterized most commonly by a feeling of heaviness in the abdomen, nausea and vomiting, gastroesophageal reflux, belching, esophagitis, heartburn, diarrhea and, at times, abdominal, back or epigastric pain and cramping.Food digestion may be slowed during this adjustment period.These symptoms can be treated with antiemetic, antispasmodic, and anticholinergic medications.Typically the stomach acclimates to the presence of the device within the first 2 weeks.In order to prevent or ameliorate the symptoms most frequently experienced during the adjustment period, it is recommended that the physician use proton pump inhibitors (ppis), antiemetics, antispasmodics, and anticholinergic medications prophylactically (before orbera® placement).Patients should be advised to immediately contact their physician for any unusually severe or worsening symptoms.The physiological response of the patient to the presence of orbera may vary depending upon the patient's general condition and the level and type of activity.The types and frequency of administration of drugs or diet supplements and the overall diet of the patient may also affect the response.Each patient must be monitored closely during the entire term of treatment in order to detect the development of possible complications.Each patient should be instructed regarding symptoms of deflation, gastrointestinal obstruction, ulceration and other complications which might occur, and should be advised to contact his/her physician immediately upon the onset of such symptoms.Adverse events: it is important to discuss all possible complications and adverse events with your patient.Complications that may result from the use of this product include the risks associated with the medications and methods utilized in the endoscopic procedure, the risks associated with any endoscopic procedure, the risks associated with the orbera intragastric balloon specifically, and the risks associated with the patient's degree of intolerance to a foreign object placed in the stomach.Us pivotal study: the event of hiccups was reported in the us pivotal clinical study and was experienced by 2.5% of the participants.
 
Event Description
Reported as: a patient with the orbera intragastric balloon had hiccups."one day after placement the [patient] came in with hiccups and was offered treatment with thorazine / levsin but the [patient] refused and just chose to have the balloon removed." the physician was unable to confirm if the removal was to hasten the resolution of the symptoms or to prevent/preclude a serious injury.Physician reported once the device was removed, the hiccups stopped.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ORBERA INTRAGASTRIC BALLOON SYSTEM
Type of Device
INTRAGASTRIC BALLOON
Manufacturer (Section D)
APOLLO ENDOSURGERY
1120 s. captial tx hwy
bldg. 1 suite 300
austin TX 78746
Manufacturer (Section G)
APOLLO ENDOSURGERY COSTA RICA, SRL
coyol free zone
building b 13.3
alajuela, costa rica
CS  
Manufacturer Contact
laura leboeuf
1120 s. captial tx hwy
bldg. 1 suite 300
austin, TX 78746
MDR Report Key6969618
MDR Text Key89997449
Report Number3006722112-2017-00371
Device Sequence Number1
Product Code LTI
UDI-Device Identifier10811955020619
UDI-Public10811955020619
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P140008
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Reporter Occupation Physician
Type of Report Initial
Report Date 09/24/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/23/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Physician
Device Model NumberB-4800
Device Catalogue NumberB-4800
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received09/24/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-